menu
    • menu
    [{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Telaglenastat

    Menu

    Telaglenastat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Calithera Biosciences

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed

                            Calithera Biosciences

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telaglenastat,Carboplatin,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

                            Details : Company will focus on advancing newly acquired targeted oncology compounds sapanisertib and mivavotinib, as well as the ongoing trial of CB-280 for the treatment of cystic fibrosis.

                            Product Name : CB-839

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 05, 2021

                            Lead Product(s) : Telaglenastat,Carboplatin,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Calithera Biosciences

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed

                            Calithera Biosciences

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telaglenastat,Cabozantinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary E...

                            Details : As compared to treatment with cabozantinib, the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival (PFS) in the study population.

                            Product Name : CB-839

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 04, 2021

                            Lead Product(s) : Telaglenastat,Cabozantinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Calithera Biosciences

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed

                            Calithera Biosciences

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telaglenastat,Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination wi...

                            Details : The new cohort of the Phase 1/2 clinical trial will be evaluating the safety and anti-tumor activity of telaglenastat in combination with palbociclib in patients with advanced, metastatic PDAC whose tumors harbor mutations in both KRAS and CDKN2A.

                            Product Name : CB-839

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 04, 2020

                            Lead Product(s) : Telaglenastat,Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Calithera Biosciences

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed

                            Calithera Biosciences

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telaglenastat,Carboplatin,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Calithera Biosciences Starts KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmun...

                            Details : Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard-of-care treatment in front-line setting among patients with non-small cell lung cancer and a mutation in the KEAP1/NRF2 pathway.

                            Product Name : CB-839

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 24, 2020

                            Lead Product(s) : Telaglenastat,Carboplatin,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth